|

Zimberelimab Clinical Trials

11 actively recruiting trials across 8 locations

▼ -1 trial since June 2026

Also known as: AB122, GLS-010, GS-0122, anti-PD-1 monoclonal antibody AB122

Pipeline

Phase 1: 4Phase 2: 5Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Gilead Sciences3
  • Tang-Du Hospital1
  • RemeGen Co., Ltd.1
  • H. Lee Moffitt Cancer Center and Research Institute1
  • Fundación GECP1

Indications

  • Cancer11
  • Cancer, Malignant Tumors1
  • Renal Carcinoma1
  • Clear Cell Renal Cell Carcinoma1
  • Resectable Lung Non-Small Cell Carcinoma1

Other3 trials

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Phase 2
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Phase 3
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Phase 2

Birmingham, Alabama1 trial

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Research Site

Phase 1

Tucson, Arizona1 trial

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The University of Arizona Cancer Center-North Campus

Phase 2

La Jolla, California1 trial

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

University of California San Diego

Phase 1

Palo Alto, California1 trial

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Stanford Cancer Center

Phase 1

New Haven, Connecticut1 trial

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Yale- New Haven Hospital- Yale Cancer Center

Phase 1

Tampa, Florida1 trial

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Moffitt Cancer Center

Phase 1/2

Boston, Massachusetts1 trial

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Beth Israel Deaconess Medical Center

Phase 2

New York, New York1 trial

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.